Lipella Pharmaceuticals Q1 2025: Grant Revenue Soars
Ticker: LIPO · Form: 10-Q · Filed: May 14, 2025 · CIK: 1347242
| Field | Detail |
|---|---|
| Company | Lipella Pharmaceuticals Inc. (LIPO) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | mixed |
Sentiment: mixed
Topics: revenue-growth, financials, 10-Q
TL;DR
Lipella's grant revenue jumped from $21 to $179k in Q1 2025. Big jump!
AI Summary
Lipella Pharmaceuticals Inc. filed its 10-Q for the period ending March 31, 2025. The company reported grant revenues of $179,448 for the first quarter of 2025, a significant increase from the $21.00 reported for the same period in 2024. Total assets were $16,646,630 as of March 31, 2025, with total liabilities at $15,340,107.
Why It Matters
The substantial increase in grant revenue suggests potential progress in the company's research and development activities or successful funding initiatives, which could impact its future growth prospects.
Risk Assessment
Risk Level: medium — The company has a significant amount of liabilities relative to its assets, indicating potential financial risk.
Key Numbers
- $179.4K — Grant Revenues (Q1 2025) (Significant increase from $21 in Q1 2024, indicating potential progress.)
- $16.6M — Total Assets (Q1 2025) (Represents the company's total resources.)
- $15.3M — Total Liabilities (Q1 2025) (Indicates the company's financial obligations.)
- $1.3M — Net Assets (Q1 2025) (Calculated as Total Assets - Total Liabilities ($16.6M - $15.3M).)
Key Players & Entities
- Lipella Pharmaceuticals Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of reporting period
- $179,448 (dollar_amount) — Grant revenues for Q1 2025
- $21.00 (dollar_amount) — Grant revenues for Q1 2024
- $16,646,630 (dollar_amount) — Total assets as of March 31, 2025
- $15,340,107 (dollar_amount) — Total liabilities as of March 31, 2025
FAQ
What is the primary driver behind the significant increase in grant revenues from $21 in Q1 2024 to $179,448 in Q1 2025?
The filing does not specify the exact reason for the increase in grant revenues, but it is a notable change from the prior year's period.
What is the total amount of Series B Preferred Stock as of March 31, 2025?
The filing indicates Series B Preferred Stock, but the specific dollar amount for March 31, 2025, is not explicitly stated in the provided snippet.
What is the total amount of Series C Preferred Stock as of March 31, 2025?
Similar to Series B, the filing mentions Series C Preferred Stock, but a specific dollar value for March 31, 2025, is not provided in the excerpt.
What were the total revenues for the quarter ending March 31, 2025?
The filing specifically mentions 'Grant revenues' of $179,448 for the period ending March 31, 2025. Other revenue streams are not detailed in this snippet.
What is the company's net income or loss for the quarter ending March 31, 2025?
The provided text snippet does not contain information regarding the company's net income or loss for the quarter.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding LIPELLA PHARMACEUTICALS INC. (LIPO).